BiotechTube

Everolimus + Sorafenib

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Differentiated Thyroid Cancer

Conditions

Differentiated Thyroid Cancer

Trial Timeline

Nov 1, 2010 → May 1, 2022

NCT ID
NCT01263951

About Everolimus + Sorafenib

Everolimus + Sorafenib is a phase 2 stage product being developed by Novartis for Differentiated Thyroid Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT01263951. Target conditions include Differentiated Thyroid Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01263951Phase 2UNKNOWN

Competing Products

20 competing products in Differentiated Thyroid Cancer

See all competitors
ProductCompanyStageHype Score
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 1/2
33
Abemaciclib + PlaceboEli LillyPhase 3
77
Lenvatinib + PlaceboEisaiPhase 3
77
LenvatinibEisaiPre-clinical
23
LenvatinibEisaiPhase 2
52
LENVATINIBEisaiPhase 2
52
Selpercatinib MonotherapyEli LillyPhase 2
52
Selumetinib + Placebo + Radioactive Iodine TherapyAstraZenecaPhase 3
77
Pembrolizumab + Cisplatin + Docetaxel + CarboplatinMerckPhase 2
52
PembrolizumabMerckPhase 2
52
sunitinib + everolimus + chemotherapies recommended in franceNovartisPre-clinical
23
Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placeboNovartisPhase 3
77
PDR001NovartisPhase 2
52
Everolimus (Afinitor®)NovartisPhase 2
52
Sacituzumab govitecanGilead SciencesPhase 2
51
sunitinibPfizerApproved
84
Vandetanib (SAR390530) + PlaceboSanofiPhase 3
76
Thyrogen (thyrotropin alfa for injection)SanofiPhase 3
76
CabazitaxelSanofiPhase 2
51
Larotrectinib monotherapyBayerPhase 2
49

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85